Syn2bio Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Cezary Kozanecki

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

No updates

Recent updates

No updates

CEO

Cezary Kozanecki

less than a year

Tenure

Mr. Cezary Dariusz Kozanecki is Chief Executive Officer and Chairman of the Management Board of Syn2bio S.A. since November 05, 2025. Mr. Kozanecki serves as Managing Director of Synektik SA. Mr. Kozanecki...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Cezary Kozanecki	CEO & Chairman of the Management Board	less than a year	no data	no data
Anna Szymanska	Member of the Management Board	less than a year	no data	no data
Sawa Zarebinska	Secretary & Member of the Supervisory Board	less than a year	no data	no data

0.7yrs

Average Tenure

Experienced Management: S2B's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sawa Zarebinska	Secretary & Member of the Supervisory Board	less than a year	no data	no data
Mariusz Ksiazek	Chairman of the Supervisory Board	less than a year	no data	no data
Piotr Chudzik	Independent Member of the Supervisory Board	no data	no data	no data
Wieslaw Latala	Independent Vice-Chairman of the Supervisory Board	less than a year	no data	no data
Robert Pikus	Independent Member of the Supervisory Board	less than a year	no data	no data

0.8yrs

Average Tenure

Experienced Board: S2B's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/08 00:11
End of Day Share Price	2026/07/08 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syn2bio S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku